

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



STARCOIN GROUP LIMITED

星太鏈集團有限公司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT IN RESPECT OF AN ONLINE MEDIA ARTICLE

This announcement is made by Starcoin Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to clarify the contents in an online media article (the “**Article**”) published on 16 October 2025 and titled “《天行健集團—星太鏈港股併購公告》發佈會” (for transliteration purpose only, “Tianxingjian Group—Starchain Hong Kong Stock Merger and Acquisition Announcement” Press Conference).

The board of directors of the Company noted that it is stated in the Article that the Company has entered into a merger and acquisition agreement with Tianxingjian Health Industry Group* (天行健健康產業集團) (“**Tianxingjian**”). The Company wishes to clarify that the content of the Article is false and untrue. The Company has not entered into any merger and acquisition agreement with Tianxingjian and has no relationship, connection or affiliation with Tianxinjian.

The Company reserves its right to take legal actions against the press and/or the relevant persons for publication of the Article containing inaccurate information and pursue other available legal remedies as it may think fit to safeguard the interests of the Company and its shareholders.

Shareholders and potential investors are advised not to rely on market rumours in relation to the Group. Any information concerning the Group should only be based on the Company's official announcements. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 20 October 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.

** For identification purpose only*